InsidersTradesSigma
Follow the Cabaletta Bio, Inc. share price and the full management transaction log of the company, a publicly traded company based in United States. Shares are quoted on the US market, under the supervision of SEC (Form 4). Operating in the Healthcare & Pharma sector, Cabaletta Bio, Inc. has published 28 public disclosures. Market capitalisation: €459.8m. The latest transaction was filed on 21 January 2026 (Acquisition). Among the most active insiders: Binder Gwendolyn. All data is openly available.
28
Insider Decl.
n/a
Thresholds
€594,257
14 ops.
Buy Volume
€8m
4 ops.
Sell Volume
50Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 21 January 2026
Declarations28 total
8,800 shares@ US$2.26100.0% of flowCommon StockSEC:0001193125-26-018327:0
Canonical exit: 21 Apr 2026 (T+90)
11,312 shares@ US$2.18917.6% of flowCommon StockSEC:0001193125-26-018325:0
Canonical exit: 21 Apr 2026 (T+90)
22,725 shares@ US$2.2144100.0% of flowCommon StockSEC:0001193125-26-018324:0
Canonical exit: 21 Apr 2026 (T+90)
22,170 shares@ US$2.265100.0% of flowCommon StockSEC:0001193125-26-018323:0
Canonical exit: 21 Apr 2026 (T+90)
4,405 shares@ US$2.266189.4% of flowCommon StockSEC:0001193125-26-018319:0
Canonical exit: 21 Apr 2026 (T+90)
45,000 shares@ US$2.239530.2% of flowCommon StockSEC:0001193125-26-018318:0
Canonical exit: 21 Apr 2026 (T+90)
11,061 shares@ US$2.283815.6% of flowCommon StockSEC:0001193125-26-018317:0
Canonical exit: 21 Apr 2026 (T+90)
6,600 shares@ US$2.2696100.0% of flowCommon StockSEC:0001193125-26-018316:0
Canonical exit: 21 Apr 2026 (T+90)
11,000 shares@ US$1.014.0% of flowCommon StockSEC:0000950170-24-005888:0
11,000 shares@ US$1.013.9% of flowCommon StockSEC:0000950170-23-071689:0
11,000 shares@ US$1.013.9% of flowCommon StockSEC:0000950170-23-065521:0
11,000 shares@ US$1.014.1% of flowCommon StockSEC:0000950170-23-054234:0
11,000 shares@ US$1.0111.3% of flowCommon StockSEC:0000950170-23-049005:0
11,000 shares@ US$1.014.0% of flowCommon StockSEC:0000950170-23-043920:0
10,700 shares@ US$13.405251.0% of flowCommon StockSEC:0000950170-23-043920:1
300 shares@ US$13.82331.5% of flowCommon StockSEC:0000950170-23-043920:2
11,000 shares@ US$1.013.8% of flowCommon StockSEC:0000899243-23-017452:0
11,000 shares@ US$1.013.9% of flowCommon StockSEC:0000899243-23-016147:0
22,000 shares@ US$1.018.0% of flowCommon StockSEC:0000899243-23-013455:0
8,127 shares@ US$1.24924.3% of flowCommon StockSEC:0000899243-22-033850:0
Canonical exit: 17 Jan 2023 (T+90)
1,000 shares@ US$0.9935100.0% of flowCommon StockSEC:0000899243-22-033783:0
Canonical exit: 16 Jan 2023 (T+90)
118,000 shares@ US$0.977100.0% of flowCommon StockSEC:0000899243-22-033781:0
Canonical exit: 16 Jan 2023 (T+90)
141,873 shares@ US$0.993958.6% of flowCommon StockSEC:0000899243-22-033779:0
Canonical exit: 16 Jan 2023 (T+90)
50,000 shares@ US$0.9924100.0% of flowCommon StockSEC:0000899243-22-033782:0
Canonical exit: 16 Jan 2023 (T+90)
20,000 shares@ US$0.99477.8% of flowCommon StockSEC:0000899243-22-033780:0
Canonical exit: 16 Jan 2023 (T+90)
25 of 28 declarations
关于 Cabaletta Bio, Inc.
Cabaletta Bio, Inc.是一家在美国纳斯达克上市的生物技术公司，专注于开发自身免疫疾病的靶向细胞疗法。该公司成立于2017年，脱胎于宾夕法尼亚大学，总部位于宾夕法尼亚州费城。其起源故事具有战略意义：Cabaletta的建立旨在将学术免疫学和细胞疗法专业知识转化为一个平台，旨在提供持久的、可能具有治愈性的治疗反应，而非长期的症状控制。([cabalettabio.com](https://www.cabalettabio.com/about?utm_source=openai)) 该公司的主要资产是rese-cel（resecabtagene autoleucel），这是一种自体CD19靶向CAR-T疗法，旨在清除致病性B细胞并重置自身免疫疾病中的免疫功能失调。Cabaletta正在通过其RESET（REstoring SElf-Tolerance）临床开发项目推进rese-cel，该项目涵盖多种疾病领域，包括系统性红斑狼疮、肌炎、系统性硬化症、重症肌无力以及寻常型天疱疮。这赋予了公司一种平台式战略：一个产品概念，多种适应症，以及跨适应症的临床和商业杠杆潜力。同时，这也意味着投资案例仍然高度依赖于临床数据、监管协调和生产执行。([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/148/cabaletta-bio-reports-first-quarter-2026-financial-results?utm_source=openai)) 从竞争角度来看，Cabaletta占据了一个独特的利基市场。它是少数专注于将CAR-T应用于自身免疫疾病的开发商之一，这个领域远不如肿瘤学领域拥挤，但商业化程度也远未得到证实。该公司一直强调实际的治疗优势，例如可能支持门诊使用的良好安全性，以及旨在提高可扩展性和资本效率的生产模式。2026年4月，Cabaletta宣布与Cellares签订了一份为期10年的rese-cel自动化生产商业供应协议，这是迈向潜在上市准备和供应链去风险化的重要一步。([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/145/cabaletta-bio-and-cellares-announce-10-year-commercial?utm_source=openai)) 在运营方面，Cabaletta的业务重心位于费城，临床活动主要集中在美国，并通过科学会议和欧洲的特定试验活动来支持国际知名度。2025年和2026年的最新公司更新显示，公司业务正从纯粹的研发转向更明确的商业化前规划：新的临床数据集已公布，2026年战略重点已概述，管理层重申了2027年提交肌炎生物制品许可申请（BLA）的目标。对于投资者而言，CABA代表了一个高风险、高回报的美国纳斯达克生物技术故事，其核心是自身免疫细胞疗法创新，但仍受制于后期开发结果的二元性质。([cabalettabio.com](https://www.cabalettabio.com/news-media/press-releases/detail/148/cabaletta-bio-reports-first-quarter-2026-financial-results?utm_source=openai))
